Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 2907-2918

  Misra, Anjan ^a,c   Pellarin, Malgorzata ^a,c   Nigro, Janice ^a,c   Smirnov, Ivan ^a,c   Moore, Dan ^a   Lamborn, Kathleen R ^a   Pinkel, Daniel ^b,c   Albertson, Donna G ^a,b,c   Feuerstein, Burt G ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASTROCYTOMA; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER GRADING; CHROMOSOME 10; CHROMOSOME 7; CHROMOSOME LOSS; CHROMOSOME MAP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEIC ACID HYBRIDIZATION; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 17144376016     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0708     Document Type: Article

References (59)

1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
2. Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Clin Cancer Res 1999;5:1435-43.
3. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG. Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 2001;61:7683-8.
4. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-8.
5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45.
6. Bissola L, Eoli M, Pollo B, et al. Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 2002;52:842-5.
7. Mohapatra G, Kim DH, Feuerstein BG. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer 1995;13:86-93.
8. Mohapatra G, Bollen AW, Kim DH, et al. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 1998;21:195-206.
9. Rutka JL, Giblin JR, Dougherty DY, et al. Establishment and characterization of five cell lines derived from human malignant gliomas. Acta Neuropathol (Berl) 1987;75:92-103.
10. Burger PC, Scheithauer BW. Tumors of the central nervous system. In: Atlas of tumor pathology. Washington (DC): Armed Forces Institute of Pathology; 1994. p. 160-378.
11. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4.
12. Misra A, Pellarin M, Shapiro JR, Feuerstein BG. A complex rearrangement of chromosome 7 in human astrocytoma. Cancer Genet Cytogenet 2004;151:162-70.
13. Sambrook J, Fritsch EF, Maniatis T. Preparation of radiolabeled DNA and RNA probes. In: Molecular cloning. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1989. p. e3-4; 10.8-10.10;10.14-10.15.
14. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. Fully automatic quantification of microarray image data. Genome Res 2002;12:325-32.
15. Hodgson G, Hager JH, Volik S, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 2001;29:459-64.
16. Mohapatra G, Moore DH, Kim DH, et al. Analyses of brain tumor cell lines confirm a simple model of relationships among fluorescence in situ hybridization, DNA index, and comparative genomic hybridization. Genes Chromosomes Cancer 1997;20:311-9.
17. Nigro JM, Takahashi MA, Ginzinger DG. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001;158:1253-62.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. Epub 2001.
20. Nigro JM, Misra A, Zhang L, et al. Molecular subgroups of human glioblastoma multiforme correlate with survival. Neuro-oncol 2003;4:313.
21. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999;1:44-51.
22. Biernat W, Debiec-Rychter M, Kordek R, Liberski PP. TP53 mutations in malignant astrocytomas. Pol J Pathol 1997;48:221-4.
23. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 2001;59:539-43.
24. Fujisawa H, Reis RM, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72.
25. Reis RM, Herva R, Brandner S, et al. Second primary glioblastoma. J Neuropathol Exp Neurol 2001;60:208-15.
26. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25.
27. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 2004;6:227-35.
28. Olson JJ, James CD, Krisht A, Barnett D, Hunter S. Analysis of epidermal growth factor receptor gene amplification and alteration in stereotactic biopsies of brain tumors. Neurosurgery 1995;36:740-8.
29. Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-53.
30. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 2003;63:413-6.
31. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene 2000;19:810-20.
32. de Silva MG, Kantharidis P, Scherer SW, et al. Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype. Cancer Genet Cytogenet 1999;110:28-33.
33. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997;57:5254-7.
34. Almeida A, Zhu XX, Vogt N, et al. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas. Oncogene 1998;16:2997-3002.
35. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
36. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503.
37. Soman NR, Wogan GN, Rhim JS. TPR-MET oncogenic rearrangement: detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell lines. Proc Natl Acad Sci U S A 1990;87:738-42.
38. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplif ication of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993;53:5535-41.
39. Ahn JY, Rong R, Kroll TG, Van Meir EG, Snyder SH, Ye K. PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem 2004;279:16441-51.
40. Hattori K, Angel P, Le Beau MM, Karin M. Structure and chromosomal localization of the functional intronless human JUN protooncogene. Proc Natl Acad Sci U S A 1988;85:9148-52.
41. Haluska FG, Huebner K, Isobe M, Nishimura T, Croce CM, Vogt PK. Localization of the human JUN protooncogene to chromosome region 1p31-32. Proc Natl Acad Sci U S A 1998;85:2215-8.
42. Ma J, Ramachandran S, Fiedorek FT Jr, Zeldin DC. Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4. Genomics 1998;49:152-5.
43. Costello JF, Plass C, Arap W, et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-4.
44. Moulton T, Samara G, Chung WY, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995;146:613-9.
45. Izumoto S, Arita N, Ohnishi T, et al. Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett 1995;97:241-7.
46. Fulci G, Labuhn M, Maier D, et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19:3816-22.
47. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-8.
48. Hegi ME, zur Hausen A, Ruedi D, Malin G, Kleihues P. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 1997;73:57-63.
49. Costello JF, Berger MS, Huang HS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-10.
50. Giordani L, Iolascon A, Servedio V, Mazzocco K, Longo L, Tonini GP. Two regions of deletion in 9p22-p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet 2002;135:42-7.
51. Grady B, Goharderakhshan R, Chang J, et al. Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. J Urol 2001;166:1088-92.
52. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer. Int J Cancer 1999;83:610-4.
53. Kim SK, Ro JY, Kemp BL, et al. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 1997;57:400-3.
54. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997;57:5254-7.
55. Sano T, Lin H, Chen X, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999;59:1820-4.
56. Bepler G, Garcia-Blanco MA. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human nonsmall-cell lung cancer. Proc Natl Acad Sci U S A 1994;91:5513-7.
57. Hu J, Jiang C, Ng HK, Pang JC, Tong CY. Chromosome 14q may harbor multiple tumor suppressor genes in primary glioblastoma multiforme. Chin Med J (Engl) 2002;115:1201-4.
58. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003;3:589-96.
59. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 2004;5:45-54.